Table 3.
Characteristics of included studies
|
Ref.
|
Study design
|
Sample size (E/C)
|
Gender (E/C) and age (yr)
|
Duration
|
Interventions
|
Period
|
Outcome measure
|
Balance report of baseline
|
|
|
Control group
|
Experimental group
|
||||||||
| Yun[27], 2014 | RCT | 48 (24/24) | (13/11) (10/14); (34.96 ± 11. 39)/(34.08 ± 12.82) | Not mentioned | Rabeprazole enteric-coated capsule | Rabeprazole enteric-coated capsule + SLBZD | 4 wk | Effective rate | P > 0.05 |
| Chen et al[28], 2014 | RCT | 79 (40/39) | (24/16) (23/16); (42.6 ± 13.1)/43.5 ± 13.4 | 6-17 mo/6-19 mo | Triple therapy (clarithromycin sustained-release tablets + rabeprazole sodium capsule + metronidazole tablets) | Triple therapy + SLBZD | 4 wk | Effective rate | P > 0.05 |
| Chen et al[29], 2018 | RCT | 60 (30/30) | (14/16) (15/15); (55.45 ± 6.55)/(55.46 ± 6.44) | 3-12 mo | Quadruple therapy (rabeprazole sodium capsule + amoxicillin + clarithromycin sustained-release tablets + biskalcitrate) | Quadruple therapy + SLBZD | 8 wk | Effective rate; H. Pylori eradication; adverse event | P > 0.05 |
| Du[30], 2017 | RCT | 48 (26/22) | (14/12) (12/10); (40.7 ± 6.1)/(41.2 ± 6.6) | 7 mo-9 years/6 mo-8 years | Quadruple therapy (amoxicillin clavulanic potassium chewable tablets + metronidazole + omeprazole + compound bismuth aluminate capsule) | SLBZD | 5 wk | Effective rate | P > 0.05 |
| Gu[31], 2017 | RCT | 98 (49/49) | Not mentioned; 19-58 | Not mentioned | Triple therapy (omeprazole + clarithromycin + amoxicillin) | Triple therapy + SLBZD | 4 wk | Effective rate; H. Pylori eradication rate; adverse event | P > 0.05 |
| Li et al[32], 2020 | RCT | 66 (33/33) | (19/14) (18/15); (58.54 ± 4.65)/(58.62 ± 4.57) | 4-17 years/4-18 years | Triple therapy (mosapride tablet + polyzyme tablets + lansoprazole tablets) | Triple therapy + SLBZD | 12 wk | Effective rate | P > 0.05 |
| Tang[33], 2014 | RCT | 60 (30/30) | (16/14) (17/13); (22-46)/(23-52) | Not mentioned | Omeprazole enteric-coated capsules | Omeprazole Enteric-coated Capsules + SLBZD | 8 wk | Effective rate | P > 0.05 |
| Xia[34], 2015 | RCT | 300 (150/150) | Not mentioned; 18-85 | Not mentioned | Omeprazole enteric-coated capsules | SLBZD | 8 wk | Effective rate; recurrence rate; adverse event | P > 0.05 |
| Xu et al[35], 2018 | RCT | 60 (30/30) | (17/13) (16/14); (55.6 ± 16.4)/(56.8 ± 14.9) | 4-20 years/4-19 years | Triple therapy (mosapride tablet + polyzyme tablets + lansoprazole tablets) | Triple therapy+SLBZD | 12 wk | Effective rate | P > 0.05 |
| Zhang et al[36], 2020 | RCT | 68 (34/34) | (15/19) (17/17); (44.8 ± 5.0)/(45.2 ± 5.4) | 1-12 years/2-14 years | Combination therapy (omeprazole + compound bismuth aluminate granules) | Combination therapy + SLBZD | 8 wk | Effective rate; adverse events | P > 0.05 |
| Zhao and Lin[37], 2010 | RCT | 80 (40/40) | (37/3) (38/2); (46.2 ± 6.7)/(44.2 ± 5.7) | 2-7 years/2-8 years | No alcohol, famotidine | No alcohol, famotidine + SLBZD | 4 wk | Effective rate; | P > 0.05 |
| Zheng[38], 2014 | RCT | 92 (46/46) | (28/18) (30/16); ( 34 ± 5.34)/( 33 ± 5.76) | 5 mo-6 years/7 mo-6 years | Triple therapy (amoxicillin dispersion tablet + omeprazole enteric-coated capsules + clarithromycin tablet) | SLBZD | 4 wk | Effective rate; adverse events; recurrence rate | P > 0.05 |
| Zhuang et al[39], 2019 | RCT | 106 (53/53) | (65/41); (46.20 ± 8.75) | 1-11 years | Triple therapy (omeprazole enteric-coated tablets + clarithromycin dispersible tablets+amoxil capsule) | Triple therapy + SLBZD | 4 wk | Effective rate; H. Pylori’s negative conversion rate | P > 0.05 |
| Zou[40], 2015 | RCT | 170 (85/85) | (86/84); (40.9 ± 11.1) | Not mentioned | Triple therapy (amoxicillin + clarithromycin + omeprazole) | Triple therapy + SLBZD | 8 wk | Effective rate; H. Pylori’s negative conversion rate; recurrence rate | P > 0.05 |
RCT: Randomized controlled trial; H. Pylori: Helicobacter pylori; SLBZS: Shen-ling-bai-zhu san.